EC Healthcare Future Growth
Future criteria checks 4/6
EC Healthcare is forecast to grow earnings and revenue by 151.5% and 8.7% per annum respectively while EPS is expected to grow by 113.8% per annum.
Key information
151.5%
Earnings growth rate
113.8%
EPS growth rate
Consumer Services earnings growth | 22.8% |
Revenue growth rate | 8.7% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 04 Nov 2024 |
Recent future growth updates
Recent updates
EC Healthcare (HKG:2138) Shares Fly 29% But Investors Aren't Buying For Growth
Dec 18EC Healthcare (HKG:2138) Will Want To Turn Around Its Return Trends
Nov 13Little Excitement Around EC Healthcare's (HKG:2138) Revenues As Shares Take 31% Pounding
Sep 05EC Healthcare (HKG:2138) Might Be Having Difficulty Using Its Capital Effectively
Jul 26EC Healthcare (HKG:2138) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 13When Should You Buy EC Healthcare (HKG:2138)?
Apr 26Is EC Healthcare (HKG:2138) A Risky Investment?
Feb 07Slammed 26% EC Healthcare (HKG:2138) Screens Well Here But There Might Be A Catch
Dec 24EC Healthcare's (HKG:2138) Dividend Is Being Reduced To HK$0.005
Dec 08Here's What's Concerning About EC Healthcare's (HKG:2138) Returns On Capital
Dec 01At HK$3.13, Is EC Healthcare (HKG:2138) Worth Looking At Closely?
Sep 15EC Healthcare (HKG:2138) Is Paying Out A Dividend Of HK$0.042
Aug 24Is EC Healthcare (HKG:2138) Using Too Much Debt?
Aug 10EC Healthcare (HKG:2138) Has Announced A Dividend Of HK$0.042
Jul 14EC Healthcare (HKG:2138) Will Pay A Dividend Of HK$0.042
Jun 26Is There Now An Opportunity In EC Healthcare (HKG:2138)?
Jun 15Be Wary Of EC Healthcare (HKG:2138) And Its Returns On Capital
May 12Is EC Healthcare (HKG:2138) Potentially Undervalued?
Mar 08EC Healthcare (HKG:2138) Will Want To Turn Around Its Return Trends
Feb 03EC Healthcare (HKG:2138) Is Paying Out Less In Dividends Than Last Year
Dec 20Is Now An Opportune Moment To Examine EC Healthcare (HKG:2138)?
Oct 25EC Healthcare (HKG:2138) Is Reinvesting At Lower Rates Of Return
Sep 20EC Healthcare's (HKG:2138) Dividend Will Be Reduced To HK$0.042
Sep 01EC Healthcare's (HKG:2138) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 28EC Healthcare's (HKG:2138) Dividend Will Be Reduced To HK$0.042
Jul 14EC Healthcare (HKG:2138) Is Reducing Its Dividend To HK$0.042
Jun 26When Should You Buy EC Healthcare (HKG:2138)?
May 26EC Healthcare (HKG:2138) Will Be Hoping To Turn Its Returns On Capital Around
Apr 18Is It Too Late To Consider Buying EC Healthcare (HKG:2138)?
Feb 24Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2026 | 4,749 | 17 | N/A | N/A | 1 |
3/31/2025 | 4,443 | 7 | N/A | N/A | 1 |
9/30/2024 | 4,153 | -12 | N/A | N/A | N/A |
6/30/2024 | 4,182 | -15 | N/A | N/A | N/A |
3/31/2024 | 4,211 | -19 | 528 | 689 | N/A |
12/31/2023 | 4,157 | -11 | 422 | 709 | N/A |
9/30/2023 | 4,104 | -4 | 317 | 729 | N/A |
6/30/2023 | 3,989 | 33 | 255 | 667 | N/A |
3/31/2023 | 3,875 | 70 | 193 | 605 | N/A |
12/31/2022 | 3,622 | 93 | 162 | 499 | N/A |
9/30/2022 | 3,369 | 117 | 132 | 392 | N/A |
6/30/2022 | 3,144 | 157 | 240 | 500 | N/A |
3/31/2022 | 2,920 | 198 | 348 | 608 | N/A |
12/31/2021 | 2,823 | 253 | 479 | 684 | N/A |
9/30/2021 | 2,727 | 309 | 610 | 760 | N/A |
6/30/2021 | 2,404 | 251 | 541 | 690 | N/A |
3/31/2021 | 2,080 | 193 | 472 | 621 | N/A |
12/31/2020 | 1,854 | 163 | 487 | 597 | N/A |
9/30/2020 | 1,627 | 133 | 503 | 573 | N/A |
6/30/2020 | 1,788 | 210 | 505 | 574 | N/A |
3/31/2020 | 1,949 | 287 | 507 | 576 | N/A |
12/31/2019 | 2,023 | 325 | 273 | 452 | N/A |
9/30/2019 | 2,098 | 364 | 40 | 327 | N/A |
6/30/2019 | 1,975 | 363 | -5 | 283 | N/A |
3/31/2019 | 1,852 | 361 | -49 | 238 | N/A |
12/31/2018 | 1,715 | 355 | 108 | 278 | N/A |
9/30/2018 | 1,578 | 348 | 265 | 317 | N/A |
6/30/2018 | 1,450 | 314 | N/A | 320 | N/A |
3/31/2018 | 1,322 | 279 | N/A | 324 | N/A |
12/31/2017 | 1,253 | 266 | N/A | 302 | N/A |
9/30/2017 | 1,183 | 253 | N/A | 280 | N/A |
6/30/2017 | 1,079 | 227 | N/A | 230 | N/A |
3/31/2017 | 975 | 201 | N/A | 180 | N/A |
12/31/2016 | 878 | 170 | N/A | 123 | N/A |
9/30/2016 | 780 | 139 | N/A | 66 | N/A |
6/30/2016 | 744 | 144 | N/A | 71 | N/A |
3/31/2016 | 708 | 149 | N/A | 76 | N/A |
12/31/2015 | 688 | 166 | N/A | 105 | N/A |
9/30/2015 | 668 | 183 | N/A | 134 | N/A |
6/30/2015 | 645 | 179 | N/A | 146 | N/A |
3/31/2015 | 621 | 174 | N/A | 159 | N/A |
3/31/2014 | 490 | 81 | N/A | 145 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2138 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: 2138 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 2138 is expected to become profitable in the next 3 years.
Revenue vs Market: 2138's revenue (8.7% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 2138's revenue (8.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2138's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 10:51 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
EC Healthcare is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Tingting Li | BOCI Research Ltd. |
Zhuonan Xu | China International Capital Corporation Limited |
null null | China International Capital Corporation Limited |